0001415889-23-013901.txt : 20231003 0001415889-23-013901.hdr.sgml : 20231003 20231003170051 ACCESSION NUMBER: 0001415889-23-013901 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230929 FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bar-Shalev Amos CENTRAL INDEX KEY: 0001385113 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 231305052 MAIL ADDRESS: STREET 1: C/O PROTALIX BIOTHERAPEUTICS, INC. STREET 2: 2 SNUNIT ST, SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 201-696-9345 MAIL ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 4 1 form4-10032023_051025.xml X0508 4 2023-09-29 0001006281 Protalix BioTherapeutics, Inc. PLX 0001385113 Bar-Shalev Amos C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET SCIENCE PARK, POB 455 CARMIEL L3 2161401 ISRAEL true false false false 0 Stock Options (Right to Buy) 1.66 2023-09-29 4 A 0 61676 0 A 2033-09-29 Common Stock 61676 61676 D The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032. /s/ Eyal Rubin, Attorney-in-Fact 2023-10-03